Lumos Pharma, Inc. (LUMO): Price and Financial Metrics
LUMO Price/Volume Stats
| Current price | $3.03 | 52-week high | $4.55 |
| Prev. close | $3.05 | 52-week low | $2.63 |
| Day low | $2.95 | Volume | 10,600 |
| Day high | $3.09 | Avg. volume | 21,993 |
| 50-day MA | $2.99 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 23.98M |
LUMO Stock Price Chart Interactive Chart >
LUMO Stock Summary
- LUMOS PHARMA INC's market capitalization of $24,218,621 is ahead of just 9.63% of US-listed equities.
- The ratio of debt to operating expenses for LUMOS PHARMA INC is higher than it is for about just 4.34% of US stocks.
- LUMO's price/sales ratio is 13.94; that's higher than the P/S ratio of 92.18% of US stocks.
- If you're looking for stocks that are quantitatively similar to LUMOS PHARMA INC, a group of peers worth examining would be PALI, OGEN, TDUP, MEIP, and XBIO.
- Visit LUMO's SEC page to see the company's official filings. To visit the company's web site, go to www.lumos-pharma.com.
LUMO Valuation Summary
- LUMO's EV/EBIT ratio is 0.3; this is 97.95% lower than that of the median Healthcare stock.
- LUMO's EV/EBIT ratio has moved up 8 over the prior 148 months.
Below are key valuation metrics over time for LUMO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LUMO | 2023-12-29 | 14.5 | 0.7 | -0.8 | 0.3 |
| LUMO | 2023-12-28 | 14.4 | 0.7 | -0.8 | 0.3 |
| LUMO | 2023-12-27 | 14.1 | 0.7 | -0.7 | 0.3 |
| LUMO | 2023-12-26 | 13.9 | 0.7 | -0.7 | 0.3 |
| LUMO | 2023-12-22 | 13.9 | 0.7 | -0.7 | 0.3 |
| LUMO | 2023-12-21 | 13.9 | 0.7 | -0.7 | 0.3 |
LUMO Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 9.4%.
- Its year over year revenue growth rate is now at 131.97%.
- Its 2 year price growth rate is now at -43.6%.
The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.231 | -26.625 | -28.456 |
| 2022-06-30 | 0.734 | -28.145 | -28.693 |
| 2022-03-31 | 0.341 | -27.269 | -29.519 |
| 2021-12-31 | 0.23 | -29.648 | -30.43 |
| 2021-09-30 | 0.05 | -30.8 | -27.204 |
| 2021-06-30 | 0.124 | -23.368 | -17.951 |
LUMO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
- LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
- INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.
The table below shows LUMO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.001 | 1 | -1.992 |
| 2021-03-31 | 0.001 | 1 | -0.861 |
| 2020-12-31 | 0.001 | 1 | -0.498 |
| 2020-09-30 | 0.004 | 1 | -0.644 |
| 2020-06-30 | 0.005 | 1 | -1.373 |
| 2020-03-31 | 0.007 | 1 | -2.610 |
LUMO Price Target
For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
Lumos Pharma, Inc. (LUMO) Company Bio
Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.
Latest LUMO News From Around the Web
Below are the latest news stories about LUMOS PHARMA INC that investors may wish to consider to help them evaluate LUMO as an investment opportunity.
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone DeficiencyWebinar to be Held December 6, 2023 at 1:30pm ESTAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in th |
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in NovemberAUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference. Piper Sandler 35th Annual Healthcare Conference: November 28th – 30th Title:Lumos Pharma Fi |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. |
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – -- OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent with Historical Growth Rates for Moderate PGHD Population – -- OraGrowtH212 Data Confirm Unique Pulsatile Mechanism of Action of LUM-201and Demonstrate Closer to Normal Physiological Growth Hormone Levels |
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary EndpointsPhase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 6 & 12 mo AHV ANCOVA Model Terms: treatment, Age at dose 1, Sex, Baseline HT SDS, Baseline BMI SDS, Baseline IGF-1 SDS, LUM-201 PEM, Baseline BA Delay, HT SDS-MPH SDS Bars represent Least Squares Mean (LSM), Error bars represent the Standard Error of LSM OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth |
LUMO Price Returns
| 1-mo | -0.98% |
| 3-mo | 4.48% |
| 6-mo | 3.77% |
| 1-year | -14.16% |
| 3-year | -83.73% |
| 5-year | -77.40% |
| YTD | -4.72% |
| 2023 | -11.91% |
| 2022 | -47.91% |
| 2021 | -80.59% |
| 2020 | 56.83% |
| 2019 | 66.45% |
Loading social stream, please wait...